About: OBJECTIVE: To report the clinical experience with anakinra for preventing mechanical ventilation (MV) in patients with COVID‐19, features of cytokine storm syndrome (CSS), and acute hypoxic respiratory failure (AHRF). METHODS: In this retrospective case series, patients must have had SARS‐CoV‐2, fever, ferritin >1,000 ng/mL with one additional laboratory marker of hyperinflammation, and AHRF. AHRF was defined as requiring 15L of supplemental oxygen via non‐rebreather mask combined with 6L nasal cannula or use of ≥95% oxygen by high flow nasal cannula. We excluded patients with suspicion for bacterial infection or on immunosuppressants. Subcutaneous anakinra was initiated at 100 mg q6 hours and gradually tapered off completely. Primary outcome was prevention of MV. RESULTS: Eleven of 14 patients meeting criteria received anakinra for a maximum of 19 days. Seven of those who initiated anakinra ≤36 hours after onset of AHRF did not require MV, and all were discharged home. Four patients who started anakinra ≥4 days after onset of AHRF required MV. Of those, 3 patients were extubated (2 discharged home, 1 remains hospitalized) and 1 died. All 3 patients who met criteria but did not receive anakinra required MV. Two were extubated (1 discharged and 1 remains hospitalized) and 1 remains on MV. CONCLUSIONS: Our data suggest that anakinra could be beneficial in COVID‐19 patients with evidence of CSS when initiated early after onset of AHRF. Our patient selection and treatment approach should be considered for investigation in a clinical trial to determine the safety and efficacy of anakinra in patients with COVID‐19 and features of CSS.

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: OBJECTIVE: To report the clinical experience with anakinra for preventing mechanical ventilation (MV) in patients with COVID‐19, features of cytokine storm syndrome (CSS), and acute hypoxic respiratory failure (AHRF). METHODS: In this retrospective case series, patients must have had SARS‐CoV‐2, fever, ferritin >1,000 ng/mL with one additional laboratory marker of hyperinflammation, and AHRF. AHRF was defined as requiring 15L of supplemental oxygen via non‐rebreather mask combined with 6L nasal cannula or use of ≥95% oxygen by high flow nasal cannula. We excluded patients with suspicion for bacterial infection or on immunosuppressants. Subcutaneous anakinra was initiated at 100 mg q6 hours and gradually tapered off completely. Primary outcome was prevention of MV. RESULTS: Eleven of 14 patients meeting criteria received anakinra for a maximum of 19 days. Seven of those who initiated anakinra ≤36 hours after onset of AHRF did not require MV, and all were discharged home. Four patients who started anakinra ≥4 days after onset of AHRF required MV. Of those, 3 patients were extubated (2 discharged home, 1 remains hospitalized) and 1 died. All 3 patients who met criteria but did not receive anakinra required MV. Two were extubated (1 discharged and 1 remains hospitalized) and 1 remains on MV. CONCLUSIONS: Our data suggest that anakinra could be beneficial in COVID‐19 patients with evidence of CSS when initiated early after onset of AHRF. Our patient selection and treatment approach should be considered for investigation in a clinical trial to determine the safety and efficacy of anakinra in patients with COVID‐19 and features of CSS. Goto Sponge NotDistinct Permalink

An Entity of Type : fabio:Abstract, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	abstract
value	OBJECTIVE: To report the clinical experience with anakinra for preventing mechanical ventilation (MV) in patients with COVID‐19, features of cytokine storm syndrome (CSS), and acute hypoxic respiratory failure (AHRF). METHODS: In this retrospective case series, patients must have had SARS‐CoV‐2, fever, ferritin >1,000 ng/mL with one additional laboratory marker of hyperinflammation, and AHRF. AHRF was defined as requiring 15L of supplemental oxygen via non‐rebreather mask combined with 6L nasal cannula or use of ≥95% oxygen by high flow nasal cannula. We excluded patients with suspicion for bacterial infection or on immunosuppressants. Subcutaneous anakinra was initiated at 100 mg q6 hours and gradually tapered off completely. Primary outcome was prevention of MV. RESULTS: Eleven of 14 patients meeting criteria received anakinra for a maximum of 19 days. Seven of those who initiated anakinra ≤36 hours after onset of AHRF did not require MV, and all were discharged home. Four patients who started anakinra ≥4 days after onset of AHRF required MV. Of those, 3 patients were extubated (2 discharged home, 1 remains hospitalized) and 1 died. All 3 patients who met criteria but did not receive anakinra required MV. Two were extubated (1 discharged and 1 remains hospitalized) and 1 remains on MV. CONCLUSIONS: Our data suggest that anakinra could be beneficial in COVID‐19 patients with evidence of CSS when initiated early after onset of AHRF. Our patient selection and treatment approach should be considered for investigation in a clinical trial to determine the safety and efficacy of anakinra in patients with COVID‐19 and features of CSS.
subject	Mechanical ventilation Intensive care medicine Emergency medical services Emergency medicine Immunosuppressants Respiratory therapy Respiratory system procedures
part of	Use of Anakinra to Prevent Mechanical Ventilation in Severe COVID‐19: A Case Series
is abstract of	Use of Anakinra to Prevent Mechanical Ventilation in Severe COVID‐19: A Case Series
is hasSource of	covid:ann/target/c2f75359c5f3df3adfc85f9636a12e6663c36c53 covid:ann/target/0fe6ddcd50aaf1a7795c39f4f86004058e34bebc covid:ann/target/616f3d0e72f4bc2bbd190dc8b4c0b3ad8e9758cc covid:ann/target/d2ce6064d63ec9267b030eea0605eb36e8c0b94e covid:ann/target/a9e86d1887d1b1aeb0ded4a501cb9991e5272bd6 covid:ann/target/9e400644cec2ed6a7c8f81006e256eee25721d85 covid:ann/target/082a3e12b95a3b32fa1edaa558ac7bd080875d9f covid:ann/target/870404f532a313c7739364e06f8af13ccc1e48c3 covid:ann/target/b35cf5ce518b0237397a84ba3a94fef9ce23e4cf covid:ann/target/3a8d6e96de92eb276a1efcb4c712595c922923e5 covid:ann/target/b61d50da4482d32c372d49a28a487b3474882dde

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software